Patent News

All the most recent news stories, updated every Tuesday, to keep you informed of the events in ever-changing and fast paced industry.

Ukraine Drafts Amendments to Patent Legislation

On February 1, 2018, a draft law aimed at improving the protection of inventions and utility models was submitted to the Ukrainian Parliament for approval. The law aims to harmonize current Ukrainian patent legislation with the following EU regulations: Directive...

read more

Apple and Nokia settle all litigation

Nokia and Apple have announced that they have settled all litigation related to their intellectual property dispute and agreed on a multi-year patent license. “This is a meaningful agreement between Nokia and Apple,” said Maria Varsellona, Chief Legal Officer at...

read more

Dentons advising Electroneum on patent request

Dentons is advising Electroneum Ltd, the early stage technology company aiming to transform the world of cryptocurrency, and which has filed a patent application for a technology that combines blockchain, cryptocurrency and mobile ubiquity. Electroneum has developed...

read more

Apple to pay $500 million to VirnetX

A notorious Patent Troll - VirnetX Holding Corporation - has won a major decision in the Eastern Court of Texas against Apple. Apple have been told in the decision that they should pay VirnetX over $500 million, in a decision that has been ongoing since 2012. In...

read more

Samsung being sued for $3 billion

A lawsuit has begun between Samsung and PACid Technologies for patent infringement of three patents. the patents in questions are believed to be related to the biometric security features of Samsung’s recent Galaxy devices; specifically, the Galaxy S6, Galaxy S7 and...

read more

Indivior sues generic versions of addiction treatment

Indivior has reacted to losing a recent court case by suing companies who are developing generic versions of its opioid addiction treatment . The Slough-based company's US arm has filed patent lawsuits against generic drugmakers Dr Reddy's, Actavis, Par, Alvogen and...

read more

Follow this link to view the 2018 edition of our yearly supplement.

Follow me on Twitter